WuXi AppTec Co Ltd (603259) - Cash Flow Conversion Efficiency
Based on the latest financial reports, WuXi AppTec Co Ltd (603259) has a cash flow conversion efficiency ratio of 0.070x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥4.24 Billion ≈ $619.79 Million USD) by net assets (CN¥60.41 Billion ≈ $8.84 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 603259 equity to assets ratio to measure how much of total assets are equity-financed.
WuXi AppTec Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how WuXi AppTec Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 603259 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
WuXi AppTec Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of WuXi AppTec Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ferrovial SE
NASDAQ:FER
|
0.024x |
|
DnB ASA
OL:DNB
|
0.400x |
|
ArcelorMittal SA ADR
NYSE:MT
|
0.000x |
|
Bank Central Asia Tbk
JK:BBCA
|
0.022x |
|
Danske Bank A/S
CO:DANSKE
|
-0.020x |
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
0.018x |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
0.124x |
|
Flex Ltd
F:FXI
|
0.082x |
Annual Cash Flow Conversion Efficiency for WuXi AppTec Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of WuXi AppTec Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of WuXi AppTec Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥59.09 Billion ≈ $8.65 Billion |
CN¥12.41 Billion ≈ $1.82 Billion |
0.210x | -12.92% |
| 2023-12-31 | CN¥55.52 Billion ≈ $8.12 Billion |
CN¥13.39 Billion ≈ $1.96 Billion |
0.241x | +6.59% |
| 2022-12-31 | CN¥46.93 Billion ≈ $6.87 Billion |
CN¥10.62 Billion ≈ $1.55 Billion |
0.226x | +91.05% |
| 2021-12-31 | CN¥38.76 Billion ≈ $5.67 Billion |
CN¥4.59 Billion ≈ $671.56 Million |
0.118x | -2.50% |
| 2020-12-31 | CN¥32.72 Billion ≈ $4.79 Billion |
CN¥3.97 Billion ≈ $581.48 Million |
0.121x | -27.49% |
| 2019-12-31 | CN¥17.41 Billion ≈ $2.55 Billion |
CN¥2.92 Billion ≈ $426.71 Million |
0.167x | +85.47% |
| 2018-12-31 | CN¥18.17 Billion ≈ $2.66 Billion |
CN¥1.64 Billion ≈ $240.05 Million |
0.090x | -66.08% |
| 2017-12-31 | CN¥6.74 Billion ≈ $985.98 Million |
CN¥1.79 Billion ≈ $262.46 Million |
0.266x | -8.14% |
| 2016-12-31 | CN¥6.06 Billion ≈ $887.12 Million |
CN¥1.76 Billion ≈ $257.07 Million |
0.290x | +152.28% |
| 2015-12-31 | CN¥6.43 Billion ≈ $940.93 Million |
CN¥738.60 Million ≈ $108.08 Million |
0.115x | -20.97% |
| 2014-12-31 | CN¥4.90 Billion ≈ $717.42 Million |
CN¥712.55 Million ≈ $104.27 Million |
0.145x | -- |
About WuXi AppTec Co Ltd
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more